vorinostat has been researched along with Follicular Thyroid Carcinoma in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Excerpt | Relevance | Reference |
---|---|---|
"In both, thyroid cancer is driven by overactivation of PI3K-AKT signaling." | 1.43 | SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model. ( Cheng, SY; Kim, DW; Willingham, MC; Zhao, L; Zhu, X, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zhu, X | 1 |
Kim, DW | 1 |
Zhao, L | 1 |
Willingham, MC | 1 |
Cheng, SY | 1 |
1 other study available for vorinostat and Follicular Thyroid Carcinoma
Article | Year |
---|---|
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Topics: Adenocarcinoma, Follicular; Animals; Carcinogenesis; Disease Models, Animal; Hydroxamic Acids; Mice, | 2016 |